6533b858fe1ef96bd12b6475

RESEARCH PRODUCT

Acetylcholinesterase inhibitors and memantine in bipolar disorder: A systematic review and best evidence synthesis of the efficacy and safety for multiple disease dimensions

Marco SolmiBrendon StubbsBrendon StubbsChristoph U. CorrellClaudio LuchiniLeonardo ZaninottoNicola VeroneseRu Band Lu

subject

Malelaw.inventionpsychosis.0302 clinical medicinePiperidinesRandomized controlled triallawDonepezilDonepezilRandomized Controlled Trials as Topicbipolar disorderClinical Trials as TopicEvidence-Based MedicineDepressionMemantineMiddle AgedManiaPsychiatry and Mental healthClinical PsychologyTreatment Outcomeacetylcholinesterase inhibitorsdepressionIndansFemalemedicine.symptomPsychologyManiamedicine.drugAdultmedicine.medical_specialtyBipolar disorderPlaceboBipolar disorder Acetylcholinesterase inhibitors Memantine Depression Mania Psychosis03 medical and health sciencesmaniaMemantineInternal medicinemedicineGalantamineHumansBipolar disorderAcetylcholinesterase inhibitors; Bipolar disorder; Depression; Mania; Memantine; Psychosis.PsychiatryDepressive DisorderGalantaminePsychosismedicine.disease030227 psychiatryAcetylcholinesterase inhibitorsMoodPsychotic DisordersAcetylcholinesterase inhibitors; Bipolar disorder; Depression; Mania; Memantine; Psychosis; Psychiatry and Mental Health; Clinical PsychologyCase-Control StudiesmemantineCholinesterase InhibitorsExcitatory Amino Acid Antagonists030217 neurology & neurosurgery

description

Abstract Background Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports. We aimed to systematically review the efficacy and safety of AceI and memantine across multiple outcome dimensions in BD. Methods Systematic PubMed and SCOPUS search until 04/17/2015 without language restrictions. Included were randomized controlled trials (RCTs), open label studies and case series of AceI or memantine in BD patients reporting quantitative data on depression, mania, psychotic symptoms, global functioning, or cognitive performance. We summarized results using a best-evidence based synthesis. Results Out of 214 hits, 12 studies (RCTs=5, other designs=7, total n=422) were included. Donepezil (studies=5; treated=102 vs. placebo=21): there was strong evidence for no effect on mania and psychotic symptoms; low evidence indicating no effect on depression. Galantamine (studies=3; treated=21 vs. controls=20) (placebo=10, healthy subjects=10): there was strong evidence for no effect on mania; moderate evidence for no effect on depression; low evidence for no effect on global functioning. Memantine (studies=4; treated=152 vs. placebo=88): there was conflicting evidence regarding efficacy for mania, depression and global functioning. Limitations Paucity of RCTs; small sample size studies; heterogeneous design, outcome and patient characteristics. Conclusion There is limited but converging evidence of no effect of AceI in BD, and conflicting evidence about memantine in BD. Too few studies of mostly medium/low quality and lacking sufficient numbers of patients in specific mood states, especially mania, contributed data, focusing solely on short-term/medium-term treatment, necessitating additional high-quality research to yield more definite results.

https://doi.org/10.1016/j.jad.2016.03.034